Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions has posted total revenues of $103.25m for the fourth quarter ended 31 December 2010, compared to $53.8m for the same period in 2009.
Subscribe to our email newsletter
Emergent‘s income from operations was $34.96m for the fourth quarter of 2010, compared to $4.13m for the same period in 2009.
The net income attributable to the company was $26.25m, compared to $4.23m for the same period, prior year.
For the full year ended 31 December 2010, the company has reported total revenues of $286.17m, compared to $234.79m for the same period in 2009.
The company’s income from operations was $73.56m, compared to $40.15m for the same period in last year.
Net income attributable was $51.7m for the full year of 2010, compared to $31.14m for the same period in 2009.
Emergent CFO Don Elsey said their 2010 financial performance reflects our continued success in growing revenue from the sale of BioThrax and government development contracts, as well as from development collaborations with our large pharma partners.
"We expect to continue our growth in 2011, as evidenced by our reaffirmed 2011 forecast of total revenues of $320 to $340m and net income of $35 to $45m," Elsey said.